In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 1, 1998, Pages 313-325

  Jones, Ronald N ^a   Ballow, Charles H ^b   Schentag, Jerome J ^b   Johnson, David M ^a   Deinhart, June A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPARFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KLEBSIELLA; MICROORGANISM; PHARMACODYNAMICS; PLASMA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS;

ANTI-INFECTIVE AGENTS; CANADA; DRUG EVALUATION, PRECLINICAL; ENTEROBACTERIACEAE; FLUOROQUINOLONES; HAEMOPHILUS; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PENICILLIN RESISTANCE; PENICILLINS; QUINOLONES; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 0031945236     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00247-2     Document Type: Article

References (39)

1. Allegra L, Lonietzko N, Leophonte P, Hosie J, Pauwels R, Gungan JN, Petitpretz P. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease a double-blind, randomized, parallel, multicentre study . J Antimicrob Chemother. 37:(suppl A):1996;93-104.
2. Aubier M, Lode H, Gialdroni-Grassi G. Sparfloxacin for the treatment of community-acquired pneumonia a pooled data analysis of two studies . J Antimicrob Chemother. 37:(suppl A):1996;73-82.
3. Ballow CH, Jones RN, Johnson DM, Schentag JJ, Deinhart JA. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis. 29:1997;173-186.
4. Baquero F, Canton R. In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother. 37:(suppl A):1996;1-18.
5. Baron EJ, Jones RN. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis. 21:1995;141-151.
6. Blondeau JM, Yaschuk Y. Canadian ciprofloxacin susceptibility study comparative study from 15 medical centers . Antimicrob Agents Chemother. 40:1996;1729-1732.
7. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wchsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 163:1991;1279-1285.
8. Bolmstrom A, Arvidson S, Ericson M, Karllsson A. A Novel Technique for Direct Quantification of Antimicrobial Susceptibility of Microorganisms (abstract 1209). 1988;ICAAC, Los Angeles, CA.
9. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. J Am Med Assoc. 271:1994;1831-1835.
10. Brown BA, Wallace RJ Jr, Flanagan CW, Wilson RW, Luman JI, Redditt SD. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 33:1989;1631-1633.
11. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 41:1997;1594-1597.
12. Brumfitt W, Hamilton-Miller JMT. Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin. J Antimicrob Chemother. 31:1993;610-612.
13. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States an update from the Centers for Disease Control and Preventions' Pneumococcal Sentinel Surveillance System . J Infect Dis. 174:1996;986.
14. Chaudry AZ, Knapp CC, ierra-Madero J, Washington JA. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 34:1990;1843-1845.
15. Cohen MA, Yoder SL, Talbot GH. Sparfloxacin world-wide in vitro literature. Diagn Microbiol Infect Dis. 25:1996;53-64.
16. Corkill JE, Percival A, McDonald P, Bamber AI. Detection of quinolone resistance in Haemophilus spp. J Antimicrob Chemother. 34:1994;841-844.
17. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in Gram-positive bacteria, enterococci, staphylococci, and non penumococcal streptococci. Drugs. 51:(suppl 1):1996;6-12.
18. Cunliffe NA, Emmanuel FXS, Thomson CJ. Lower respiratory tract infection due to ciprofloxacin-resistant Moraxella catarrhalis. J Antimicrob Chemother. 36:1995;273-274.
19. Doern MA, Brueggeman A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995 results of a 30-center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
20. Doern GV, Ferraro MJ, Brueggeman AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 40:1996;891-894.
21. Fu KP, Lafredo SC, Foleno B. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 36:1992;860-868.
22. Fuchs PC, Barry AL, Pfaller MA. Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. J Clin Microbiol. 31:1993;2236-2237.
23. Gehanno P, Berche P. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother. 37:(suppl A):1996;105-114.
24. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-146.
25. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP) a strategy from the DRSP working group . J Am Med Assoc. 275:1996;206-209.
26. Jones RN, Jacobs MR, Washington JA, Pfaller MA. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis. 27:1997;75-83.
27. Jones RN, Kehrberg EN, Erwin ME, Anderson SC. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances Real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
28. Kayser FH, Wust J. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. Eur J Clin Microbiol Infect Dis. 10:1991;163-166.
29. Klugman KP. Epidemiology, control and treatment of multiresistant pneumococci. Drugs. 52:(suppl 2):1996;42-46.
30. Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 33:1989;1980-1988.
31. Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 34:1990;1123-1127.
32. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (4th ed). Approved Standard M7-A4. 1997;NCCLS, Villanova, PA.
33. Performance Standards for Antimicrobial Disk Susceptibility Tests (6th ed). Approved Standard M2-A6. 1997;NCCLS, Villanova, PA.
34. Performance Standards for Antimicrobial Susceptibility Testing. Approved Standard M100-S8. 1998;NCCLS, Villanova, PA.
35. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 110:1996;1499-1506.
36. Panililio A, Culver DH, Gaynes RP. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
37. Pfaller MA, Jones RN. Comparative anti-streptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagn Microbiol Infect Dis. 29:1997;199-201.
38. Sanchez ML, Jones RN. Etest, a antimicrobial susceptibility testing method with broad clinical and epidemiologic application. Antimicrob Newslett. 8:1992;1-8.
39. Washington JA. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994; The Alexander Project. Diagn Microbiol Infect Dis. 25:1996;183-190.